Home Infusion is growing as new drugs are approved, therapies are added and the population ages. Home infusion is projected to grow by 64% in the next three years and by 2020, the global home infusion market is estimated to reach $27B1. Specialty pharmacy costs are expected to grow 28% year over year2, growing faster than other medical costs.
Home Infusion therapy is considered a loosely managed segment of the care continuum and payors have historically done little to manage drugs on the medical side: Health plans have “historically focused on the pharmacy benefit, but can do more to manage medications paid for under the medical benefit.” Other challenges that payors face including managing across the pharmacy / medical benefit, ensuring clinically appropriate use of specialty drugs and monitoring the extremely active pipeline of new drugs including the exponential growth in oncology drugs.
Dr. Michael Cantor
Chief Medical Officer
Dr. Cantor is a geriatrician and attorney with over 20 years’ experience in designing and implementing population health and quality improvement programs for health plans and healthcare providers. He is currently Chief Medical Officer (CMO) for CareCentrix, a post-acute benefits management company, and prior to that served as CMO for a large physician network for an academic medical center in Boston, where he managed network-wide population health and quality improvement programs. He also served as founding Medical Director for a Medicare Shared Savings Accountable Care Organization (ACO), and founding CMO for Minuteman Health, a CO-OP insurance plan, where he developed and implemented medical management programs. He has also served as medical director for Medicare Advantage and institutional and dual Special Needs Plans. He also held positions at provider organizations in New England, where he was oversaw and managed new clinical programs for older people, including geriatric assessments, primary care, long term care, palliative care, and house calls programs. He trained in internal medicine at Beth Israel Hospital in Boston, and did his geriatrics fellowship at Harvard Medical School. His degrees in law and medicine are from the University of Illinois.
VP of Business Development and Strategy
Anne Wong is VP of Business Development and Strategy at CareCentrix where she is responsible for both strategy development and execution of strategic initiatives. Prior to CareCentrix, Anne was a principal with management consulting firm, Booz & Company (now Strategy&, a PwC Company). As a consultant, Anne focused on developing strategies to evolve the financing and delivery models for healthcare services organizations. Her clients included national and regional health plans and health systems as well as more niche ancillary healthcare companies. While she was at Booz, Anne co-authored a number of publications on bundled care products and M&A strategy in light of the evolving US healthcare system. She has an MBA from the University of Chicago Booth School of Business and a BS from Northwestern University. She resides in Chicago with her husband and two young children.
 Persistence Market Research (PMR), “Home Infusion Therapy Market Will Reach USD 26.7 billion in 2020.” May 2015.
 Authors: Brian Bruen and Katherine Young. Published by Kaiser Family Foundation, 12/10/14